I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024

May 23, 2024

https://www.globenewswire.com/news-release/2024/05/23/2887703/0/en/I-Mab-Announces-Encouraging-Phase-1-Clinical-Data-of-PD-L1x4-1BB-Bispecific-Antibody-Ragistomig-at-ASCO-2024.html

ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) — I-Mab (the “Company”) (NASDAQ:IMAB) a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that Gerald Falchook, MD, and the team at I-Mab’s partner for ragistomig (or “ABL503”), ABL Bio (KOSDAQ: 298380), will present a poster related to Phase 1 data for ragistomig at the 2024 American Society for Clinical Oncology Annual Meeting (“ASCO 2024”), taking place from May 31st to June 4th at the McCormick Place Convention Center in Chicago, IL.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.